NCT04233567: Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations

NCT04233567
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have received at least one prior standard of care regimen for advanced/metastatic cancer
Exclusions: Patients with symptomatic untreated CNS metastases – see trial for details
https://ClinicalTrials.gov/show/NCT04233567

Comments are closed.

Up ↑